EGFR and lung adenocarcinoma: In conclusion, in our study of patients with stage IIIb or IV lung adenocarcinoma with EGFR mutations who received TKIs as the first-line treatment, a lower lymphocyte percentage, and higher platelet counts were significantly associated with shorter PFS and OS.